

01-97000-06

Original Effective Date: 12/15/02

Reviewed: 10/27/22

Revised: 09/15/23

## Subject: Pelvic Floor Stimulation as a Treatment of Incontinence

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

<a href="#">Position Statement</a>	<a href="#">Billing/Coding</a>	<a href="#">Reimbursement</a>	<a href="#">Program Exceptions</a>	<a href="#">Definitions</a>	<a href="#">Related Guidelines</a>
<a href="#">Other</a>	<a href="#">References</a>	<a href="#">Updates</a>			

### DESCRIPTION:

Pelvic floor stimulation (PFS) is proposed as a nonsurgical treatment option for women and men with urinary incontinence. This approach involves either electrical stimulation of pelvic floor musculature or extracorporeal pulsed magnetic stimulation. Electrical stimulation of the pelvic floor is also proposed as a treatment of fecal incontinence. Pelvic floor stimulation (PFS) involves electrical stimulation of pelvic floor muscles using either a probe wired to a device for controlling the electrical stimulation or, more recently, extracorporeal electromagnetic (also called magnetic) pulses.

### POSITION STATEMENT:

Electrical or magnetic stimulation of the pelvic floor muscles as a treatment for urinary [incontinence](#) is considered **experimental or investigational**. Data in published medical literature are inadequate to permit scientific conclusions on long-term and net health outcomes.

Electrical or magnetic stimulation of the pelvic floor muscles as a treatment for fecal incontinence or chronic constipation is considered **experimental or investigational**. Data in published medical literature are inadequate to permit scientific conclusions on long-term and net health outcomes.

### BILLING/CODING INFORMATION:

The following codes may be used:

#### CPT Coding:

97014	Application of a modality to one <b>OR</b> more areas; electrical stimulation (unattended)
-------	--

97032	Application of a modality to 1 <b>OR</b> more areas; electrical stimulation (manual), each 15 minutes (one-on-one contact)
-------	--

### HCPCS Coding:

E0740	Non-implanted pelvic floor electrical stimulator, complete system ( <b>Investigational</b> )
G0283	Electrical stimulation (unattended), to one <b>OR</b> more areas for indication(s) other than wound care, as part of a therapy plan of care

### REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

### PROGRAM EXCEPTIONS:

**Federal Employee Program (FEP):** Follow FEP guidelines.

**State Account Organization (SAO):** Follow SAO guidelines.

**Medicare Advantage products:** The following National Coverage Determination (NCD) was reviewed on the last guideline reviewed date: Non-Implantable Pelvic Floor Electrical Stimulator (230.8) located at [cms.gov](https://www.cms.gov).

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

### DEFINITIONS:

**Functional incontinence:** a type of incontinence when getting to and using the toilet when the need arises is the cause. There may be musculoskeletal problems that prevent the sufferer from moving quickly enough to get to the bathroom, remove clothing to use the toilet, or transfer from a wheelchair to a toilet. Musculoskeletal problems include back pain or arthritis. There may also be neurological problems such as Parkinson's disease or multiple sclerosis (MS). In other cases, functional incontinence may result from problems with thinking or communicating.

**Mixed incontinence:** results from both stress and urge symptoms and causes.

**Overflow incontinence:** this results from overdistension of the bladder. There may be urine dribbling and urge or stress incontinence symptoms. This may result from drugs, a neurologic condition such as diabetic neuropathy, bladder outlet or urethral obstruction, BPH or uterine/bladder prolapses.

**Stress incontinence:** an involuntary loss of urine when coughing, laughing, sneezing, etc., commonly caused by displacement of the urethra and bladder neck or urethral sphincter deficiency. Childbirth in women may contribute to this development and in males, may occur after a prostatectomy.

**Transient incontinence:** a type of incontinence that often disappears in time or after treatment. Causes may include alcohol and drug use, heart failure, venous insufficiency, inflammation of the urethra or the vagina, sexually transmitted diseases or urinary tract infections.

**Urge incontinence:** an abrupt, strong desire to void, resulting in the involuntary loss of urine. It may be associated with involuntary detrusor contractions (detrusor overactivity or instability) and/or several other factors (disease, drugs).

## RELATED GUIDELINES:

[Sacral Nerve Modulation/Stimulation, 02-61000-23](#)

[Posterior Tibial Nerve Stimulation for Voiding Dysfunction, 02-64000-01](#)

## OTHER:

**Note:** The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another and is not intended to represent a complete listing of all products available.

Other names used to report **electrical pelvic floor stimulation:**

ApexM®  
EmbaGYN®  
Pathway™ CTS 2000  
MyoTrac Infiniti™  
InCare® PRS  
InTone®

Other names used to report **magnetic pelvic floor stimulation:**

Extracorporeal Electromagnetic Stimulation  
NeoControl® Pelvic Floor Therapy System  
BTL EMSELLA®  
High Intensity Focused ElectroMagnetic Energy (HIFEM)

## REFERENCES:

1. Abrams P, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and Treatment of Urinary Incontinence, Pelvic Organ Prolapse, and Fecal Incontinence. *Neurourology and Urodynamics* 29:213–240 (2010).
2. AHRQ National Guideline Clearinghouse. NGC-4011. Management of urinary incontinence in primary care. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2004 Dec.
3. AHRQ Guideline Clearinghouse. NGC-6743. Urinary Incontinence in Women. Finnish Medical Society Duodecim. Urinary incontinence in women. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2008 Aug 8.
4. AHRQ National Guideline Clearinghouse. NGC- 6801. Conservative Management of Urinary Incontinence. Society of Obstetricians and Gynaecologists of Canada, Robert M, Ross S, Farrel SA, Easton WA, Epp A, Girouard L, Gupta C, Lajoie F, Lovatsis D, MacMillan B, Schachter J, Schulz J,

Wilkie DH. Conservative management of urinary incontinence. *J Obstet Gynaecol Can* 2006 Dec;28(12):1113-8.

5. AHRQ National Guideline Clearinghouse. NGC-7325. Incontinence in men. In: *Guidelines on urinary incontinence*. Arnhem, The Netherlands: European Association of Urology (EAU); 2009 Mar.
6. AHRQ National Guideline Clearinghouse. NGC-7884. (1) Incontinence in women. In: *Guidelines on urinary incontinence*. (2) 2010 addendum to 2009 urinary incontinence guidelines. Arnhem, The Netherlands: European Association of Urology (EAU); 2009 Mar. p. 28-43. 2010 Addendum to 2009 Guideline Summary.
7. AHRQ National Guideline Clearinghouse. NGC-7873. Recommendations for the management of urge urinary incontinence in women. Austin (TX): University of Texas at Austin, School of Nursing; 2010 May.
8. AHRQ National Guideline Clearinghouse. NGC-8401. Urinary incontinence. Columbia (MD): American Medical Directors Association (AMDA); 2010.
9. AHRQ National Guideline Clearinghouse. NGC-9099. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP. Linthicum (MD): American Urological Association (AUA); 2012 May.
10. AHRQ Agency for Healthcare Research and Quality (AHRQ). *Guideline Syntheses: Assessment and Management of Urinary Incontinence in Women*. Revised March 2010.
11. American College of Obstetricians and Gynecologists. FAQ081: Gynecologic Problems; Urinary Incontinence. May 2011.
12. American Urological Association. *Guideline for the Surgical Management of Female Stress Urinary Incontinence: 2009 Update*. ©2009 American Urological Association, Inc.
13. Blue Cross Blue Shield Association Evidence Positioning System®. 1.01.17 - Pelvic Floor Stimulation as a Treatment of Urinary and Fecal Incontinence, 09/22.
14. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). – “Magnetic Stimulation in the Treatment of Urinary Incontinence in Adults” TEC Assessments 2000, Tab 8.
15. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). “Pelvic Floor Electrical Stimulation in the Treatment of Urinary Incontinence in Adults” TEC Assessments 2000, Tab 2.
16. Blue Cross Blue Shield of Florida Technology Assessment “Electric Stimulation for the Treatment of Urinary Incontinence” January 1996.
17. Braga A, Castronovo F, Caccia G, Papadia A, Regusci L, Torella M, Salvatore S, Scancarello C, Ghezzi F, Serati M. Efficacy of 3 Tesla Functional Magnetic Stimulation for the Treatment of Female Urinary Incontinence. *J Clin Med*. 2022 May 16;11(10):2805. doi: 10.3390/jcm11102805.
18. Bruscianno L, Gambardella C, Gualtieri G, Terracciano G, Tolone S, Schiano di Visconte M, Grossi U, Del Genio G, Docimo L. Effects of Extracorporeal Magnetic Stimulation in Fecal Incontinence. *Open Med (Wars)*. 2020 Jan 30; 15:57-64. doi: 10.1515/med-2020-0009.
19. California Technology Assessment Forum (CTAF). *Electrical Stimulation for the Treatment of Urinary Incontinence in Women*. Technology Assessment. San Francisco, CA: October 20, 2004.
20. California Technology Assessment Forum (CTAF). *Magnetic Stimulation for the Treatment of Urinary Incontinence in Women*. Technology Assessment. San Francisco, CA: October 20, 2004.
21. Canning A, Raison N, Aydin A, Cheikh Youssef S, Khan S, Dasgupta P, Ahmed K. A systematic review of treatment options for post-prostatectomy incontinence. *World J Urol*. 2022 Nov;40(11):2617-2626. doi: 10.1007/s00345-022-04146-5. Epub 2022 Sep 15.
22. Castro, Rodrigo A., Arruda, Raquel M., Zanetti, Miriam R. D. et al. Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active

treatment in the management of stress urinary incontinence. *Clinics*, 2008, vol.63, no.4, p.465-472. ISSN 1807-5932.

23. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Non-Implantable PELVIC FLOOR Electrical Stimulator (230.8) (06/19/06).
24. ClinicalTrials.gov. Conservative Treatment of Postprostatectomy Incontinence. NCT00212264. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Last updated April 25, 2012.
25. ClinicalTrials.gov. Vaginal Electrical Stimulation versus Neuromodulation. NCT01525485. University of Oklahoma. Last updated August 7, 2012.
26. Doganay M, Kilic S, Yilmaz N. Long-term effects of extracorporeal magnetic innervations in the treatment of women with urinary incontinence: results of 3-year follow-up. *Arch Gynecol Obstet*. 2010 Jul;282(1):49-53. doi: 10.1007/s00404-009-1243-5. Epub 2009 Oct 16. PMID: 19834722.
27. ECRI Clinical Evidence Assessment. Emsella Electromagnetic Stimulation System (BTL Industries, Inc.) for Treating Urinary Incontinence. 2022.
28. ECRI Health Technology Assessment Information Services – Custom Hotline Response “Pelvic Floor Stimulation for Treatment of Urinary Incontinence” 05/10/05.
29. ECRI Health Technology Assessment Information Services – Windows on Medical Technology “Magnetic Muscle Stimulation for the Treatment of Urinary Incontinence” 04/02.
30. First Coast Service Options, Inc. (FCSO). Local Coverage Determination (LCD): Therapy and Rehabilitation Services (L33413) (10/01/15) (revised 01/01/19).
31. Florida Medicare Part B Local Coverage Determination. L6196 THERSVCS Therapy and Rehabilitation Services 07/01/08. Retired 02/01/09.
32. Florida Medicare Part B Local Coverage Determination. Therapy and Rehabilitative Services (L29289). Last revised 01/01/13. (Retired 09/30/15).
33. Galloway NT, El-Galley RE, Sand PK, Appell RA, Russell HW, Carlin SJ. Update on extracorporeal magnetic innervation (EXMI) therapy for stress urinary incontinence. *Urology*. 2000 Dec 4;56(6 Suppl 1):82-6. doi: 10.1016/s0090-4295(00)00686-5. PMID: 11114568.
34. Gillling PJ, et al. A double-blind randomized controlled trial of electromagnetic stimulation of the pelvic floor vs sham therapy in the treatment of women with stress urinary incontinence. *BJU International* 103, 1386-1390 (2009).
35. Goode PS, Burgio KL, Locher JL, Roth DL, Umlauf MG, Richter HE, Varner RE, Lloyd LK. Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women: a randomized controlled trial. *JAMA*. 2003 Jul 16; 290(3): 345-52.
36. Gumussoy S, Kavlak O, Yeniel AO. Effects of Biofeedback-Guided Pelvic Floor Muscle Training With and Without Extracorporeal Magnetic Innervation Therapy on Stress Incontinence: A Randomized Controlled Trial. *J Wound Ostomy Continence Nurs*. 2021 Mar-Apr 01;48(2):153-161. doi: 10.1097/WON.0000000000000740. PMID: 33690249.
37. Hayes, Inc. Hayes Medical Technology Directory. Pelvic Floor Electrical Stimulation for the Treatment of Urinary Incontinence. Lansdale, PA: Hayes, Inc.; March 2006. Update performed 03/26/08.
38. Hayes, Inc. Hayes Medical Technology Directory. Extracorporeal Magnetic Stimulation for Urinary Incontinence. Lansdale, PA: Hayes, Inc.; July 2003. Update performed 04/13/08.
39. Holroyd-Leduc JM, Straus SE. Management of urinary incontinence in women: scientific review. *JAMA*. 2004 Feb 25; 291(8): 986-95.
40. Hoscan MB, Dilmen C, Perk H, Soyupek S, Armağan A, Tükel O, Ekinci M. Extracorporeal magnetic innervation for the treatment of stress urinary incontinence: results of two-year follow-up. *Urol Int*. 2008;81(2):167-72. doi: 10.1159/000144055. Epub 2008 Aug 29.

41. Hwang UJ, Lee MS, Jung SH, Ahn SH, Kwon OY. Effect of pelvic floor electrical stimulation on diaphragm excursion and rib cage movement during tidal and forceful breathing and coughing in women with stress urinary incontinence: A randomized controlled trial. *Medicine (Baltimore)*. 2021 Jan 8;100(1): e24158. doi: 10.1097/MD.00000000000024158.
42. Imamura M, Abrams P, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. *Health Technol Assess*. 2010 Aug;14(40):1-188, iii-iv.
43. Jha S, et al. Impact of pelvic floor muscle training on sexual function of women with urinary incontinence and a comparison of electrical stimulation versus standard treatment (IPSU trial): a randomised controlled trial. *Physiotherapy*. 2018 Mar;104(1):91-97. doi: 10.1016/j.physio.2017.06.003. Epub 2017 Jun 23.
44. Kannan P, et al. Effectiveness of Pelvic Floor Muscle Training Alone and in Combination with Biofeedback, Electrical Stimulation, or Both Compared to Control for Urinary Incontinence in Men Following Prostatectomy: Systematic Review and Meta-Analysis. PMID: 30137629.
45. Knorst, Mara R. et al. Physical therapy intervention in women with urinary incontinence associated with pelvic organ prolapse. *Rev. bras. fisioter.*, São Carlos, v. 16, n. 2, Apr. 2012. Available at: [http://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S1413-35552012000200004&lng=en&nrm=iso](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-35552012000200004&lng=en&nrm=iso)
46. Kobashi KC, Albo ME, Dmochowski RR et al: Surgical Treatment of Female Stress Urinary Incontinence: AUA/SUFU Guideline. *J Urol* 2017; 198: 875.
47. Komesu YN, et al. Refractory urgency urinary incontinence treatment in women: impact of age on outcomes and complications. *Am J Obstet Gynecol*. 2018 Jan;218(1): 111.e1-111.e9. doi: 10.1016/j.ajog.2017.10.006. Epub 2017 Oct 12.
48. Landefeld CS, Bowers BJ, Feld AD, Hartmann KE, Hoffman E, Ingber MJ, King JT, McDougal WS, Nelson H, Orav EJ, Pignone M, Richardson LH; Rohrbaugh RM, Siebens HC, Trock BJ. National Institutes of Health State-of-the-Science Conference Statement: Prevention of Fecal and Urinary Incontinence in Adults. *Ann Intern Med*. 2008 Mar;148(6):449-58.
49. Lapitan MC, Cody JD, Grant A. Open retropubic colposuspension for urinary incontinence in women: a short version Cochrane review. *Neurourol Urodyn*. 2009;28(6):472-80. doi: 10.1002/nau.20780.
50. MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ. Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness. *BJU INT*. 2007 Jul; 100(1): 76-81. Epub 2007 Apr 13.
51. Magali R, Ross S. The Society of Obstetricians and Gynaecologists of Canada. Clinical Practice Guideline: Conservative Management of Urinary Incontinence. No. 186, December 2006.
52. Massimo R, Sighinolfi MC, Micali S, De Stefani S, Bianchi G. Sexual Function and Quality of Life in Women with Urinary Incontinence Treated by a Complete Pelvic Floor Rehabilitation Program (Biofeedback, Functional Electrical Stimulation, Pelvic Floor Muscles Exercises and Vaginal Cones). *The Journal of Sexual Medicine*, Vol. 7, #3, p. 1039-1316. March 2010.
53. Mazur-Bialy AI, Kołomańska-Bogucka D, Nowakowski C, Tim S. Urinary Incontinence in Women: Modern Methods of Physiotherapy as a Support for Surgical Treatment or Independent Therapy. *J Clin Med*. 2020 Apr 23;9(4):1211. doi: 10.3390/jcm9041211.
54. Mikus M, Kalafatic D, Vrbancic A, et al. Efficacy Comparison between Kegel Exercises and Extracorporeal Magnetic Innervation in Treatment of Female Stress Urinary Incontinence: A Randomized Clinical Trial. *Medicina (Kaunas)*. 2022 Dec 17;58(12):1863. doi: 10.3390/medicina58121863.
55. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 40. Urinary incontinence: the management of urinary incontinence in women, October 2006. Available at: [www.nice.org.uk](http://www.nice.org.uk).

56. National Institute for Health and Clinical Excellence (NICE). NICE Guideline 210. December 2021. Available at [www.nice.org.uk](http://www.nice.org.uk).
57. National Institutes of Health Consensus and State-of-the Science Statements. Prevention of Fecal and Urinary Incontinence in Adults. Volume 24, Number 1 (2007).
58. Neumann PB, Grimmer KA, Deenadayalan Y. Pelvic floor muscle training and adjunctive therapies for the treatment of stress urinary incontinence in women: a systematic review. *BMC Women's Health*. 2006 Jun 28; 6:11.
59. Rivalta M, Sighinolfi MC, Micali S. Urinary Incontinence and Sport: First and Preliminary Experience with a Combined Pelvic Floor Rehabilitation Program in Three Female Athletes. *Health Care for Women International*, 31:435–443, 2010.
60. Shamliyan T, Wyman J, Bliss DZ, Kane RL, Wilt TJ. Prevention of Fecal and Urinary Incontinence in Adults. Evidence Report/Technology Assessment No. 161 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.) AHRQ Publication No. 08-E003. Rockville, MD. Agency for Healthcare Research and Quality. December 2007. Structured Abstract.
61. Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomized, controlled trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med*. 2008 Mar 18; 148(6): 459-73. Epub 2008 Feb 11.
62. Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr. (Comparative Effectiveness Reviews, No. 36.) Available at: <http://www.ncbi.nlm.nih.gov/books/NBK92960/>.
63. Unsal A, Saglam R, Cimentepe E. Extracorporeal magnetic stimulation for the treatment of stress and urge incontinence in women--results of 1-year follow-up. *Scand J Urol Nephrol*. 2003;37(5):424-8. doi: 10.1080/00365590310021258. PMID: 14594693.
64. UpToDate. Female urinary incontinence: Treatment. 2023. Accessed at [uptodate.com](http://uptodate.com).
65. UpToDate. Management of bladder dysfunction in children. 2021. Accessed at [uptodate.com/](http://uptodate.com/)
66. UpToDate. Treatment of urinary incontinence in females. 2020. Accessed at [uptodate.com](http://uptodate.com).
67. U.S. Food and Drug Administration (FDA). 510(K). Summary of safety and effectiveness K090750, RT300. 2009.
68. U.S. Food and Drug Administration (FDA). 510(k) Summary K181497: HPM-6000UF (EMSELLA®) (November 2018).
69. Wald A. Diagnosis and Management of Fecal Incontinence. *Curr Gastroenterol Rep*. 2018 Mar 26;20(3):9. doi: 10.1007/s11894-018-0614-0. PMID: 29582182.
70. Wallis MC et al. Pelvic Static Magnetic Stimulation to Control Urinary Incontinence in Older Women: A Randomized Controlled Trial. *Clinical Medicine & Research* Volume 10, Number 1: 7-14. (2012).
71. Weber-Rajek M, Radziwińska A, Strączyńska A, Podhorecka M, Kozakiewicz M, Perkowski R, Jarzemski P, Kędziora-Kornatowska K, Goch A. A randomized-controlled trial pilot study examining the effect of extracorporeal magnetic innervation in the treatment of stress urinary incontinence in women. *Clin Interv Aging*. 2018 Dec 4;13:2473-2480. doi: 10.2147/CIA.S176588.
72. Weber-Rajek M, Strączyńska A, Strojek K, et al. Assessment of the Effectiveness of Pelvic Floor Muscle Training (PFMT) and Extracorporeal Magnetic Innervation (ExMI) in Treatment of Stress Urinary Incontinence in Women: A Randomized Controlled Trial. *Biomed Res Int*. 2020 Jan 16;2020:1019872. doi: 10.1155/2020/1019872.
73. Yamanishi T, Kamai T, Yoshida K. Neuromodulation for the treatment of urinary incontinence. *Int J Urol*. 2008 Aug;15(8):665-72. doi: 10.1111/j.1442-2042.2008.02080.x. Epub 2008 Jun 2.

74. Yokoyama T, Fujita O, Nishiguchi J, Nozaki K, Nose H, Inoue M, Ozawa H, Kumon H. Extracorporeal magnetic innervation treatment for urinary incontinence. *Int J Urol*. 2004 Aug;11(8):602-6. doi: 10.1111/j.1442-2042.2004.00857.x. PMID: 15285749.

### COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 10/27/22.

### GUIDELINE UPDATE INFORMATION:

12/15/02	Reformat, review & revision of original Medical Coverage Guideline (10/95).
04/15/03	HCPCS coding update; added G0283.
12/15/03	Review of guideline; no change in coverage statement.
12/15/04	Review and revision of guideline; consisting of updated references.
01/01/06	Review and revision of guideline; consisting of updated references.
11/15/06	Review and revision of guideline consisting of updated references.
07/15/07	Review and revision of guideline consisting of updated references and reformatted guideline.
11/15/08	Scheduled review; no change in position statement. Update references.
01/01/09	Annual HCPCS coding update: deleted 0029T.
11/15/09	Scheduled review; no change in position statement. Update references.
01/01/10	Annual HCPCS coding update: revised descriptor for code 97032.
11/15/10	Scheduled review. No change in position statement; references updated.
11/15/11	Scheduled review. Update description section, maintain position statement and update references.
10/15/12	Scheduled review. Added coverage statement (E/I) for electrical or magnetic stimulation of the pelvic floor muscles for treatment of fecal incontinence and chronic constipation. Revised description and definitions. Updated references.
10/15/13	Scheduled review. Position statement maintained. Revised program exceptions section. Updated references.
11/01/15	Revision: ICD-9 Codes deleted.
01/01/17	Annual CPT/HCPCS update. Revised E0740 descriptor.
09/15/19	Scheduled review. Maintained position statement, Revised description, Medicare Advantage program exception, and index terms. Updated references.
03/15/21	Scheduled review. Revised description and program exceptions. Maintained position statement and updated references.
11/15/22	Scheduled review. Revised description, maintained position statement and updated references.
05/22/23	Update to Program Exceptions section.
09/15/23	Revision. Updated references. Revised index terms and maintained position statement.